Laser-Capture Microdissection and Analysis of Liver Endothelial Cells from Patients with Budd–Chiari Syndrome

Methods in Molecular Biology

Volumn 755, Issue , 2011, Pages 405-415

  Sozer, Selcuk ^a,b   Hoffman, Ronald ^b,c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Myeloproliferative Disorder Research Consortium   (United States)

Author keywords

Laser capture microdissection; Myeloproliferative neoplasms; Polymerase chain reaction

Indexed keywords

CD34 ANTIGEN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MESSENGER RNA;

ARTICLE; BUDD CHIARI SYNDROME; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LASER; LIVER; METABOLISM; METHODOLOGY; MICRODISSECTION; MICROTOMY; MISSENSE MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

ANTIGENS, CD34; BUDD-CHIARI SYNDROME; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; JANUS KINASE 2; LASERS; LIVER; MICRODISSECTION; MICROTOMY; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STAINING AND LABELING;

EID: 79960943078     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-163-5_34     Document Type: Chapter

References (13)

1. Tefferi A, Elliott M. (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33, 313–320.
2. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. (2006) Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 159–66.
3. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica. 92, 135–136.
4. Robertson B, Urquhart C, Ford I, et al (2007). Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphos-pholipid antibodies. J Thromb Haemost. 5, 1679–1685.
5. Bellucci S, Michiels JJ. (2006) The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 32, 381–398.
6. Duda DG, Fukumura D, Jain RK. (2004) Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 10, 143–145.
7. Kiladjian JJ, Cervantes F, Leebeek FW, et al. (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 111, 4922–4929.
8. Patel RK, Lea NC, Heneghan MA, et al. (2006) Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome. Gastroenterology. 130, 2031–2038.
9. Espina V, Wulfkuhle JD, Calvert V. et al. (2006) Laser-capture microdissection. Nature Protocols. Nat Protoc. 1, 586–603.
10. Sozer S, Fiel MI, Schiano T, et al. (2009) The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 113, 5246–5249.
11. Zengin E, Chalajour F, Gehling UM, et al. (2006) Vascular wall resident progenitor cells: a source for postnatal vasculogenesis. Development. 133, 1543–1551.
12. Ergun S, Tilki D, Hohn HP, Gehling U, Kilic N. (2007) Potential implications of vascular wall resident endothelial progenitor cells. Thromb Haemost. 98, 930–939.
13. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. (1999) Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 27, 4436–4443.